Intra-Cellular Therapies Announces Positive Topline Results from Study 403 Evaluating Lumateperone as Monotherapy in Patients with Major Depressive Disorder with Mixed Features and Bipolar Depression ...

Credit: Getty Images. Lumateperone 42mg given once daily met the primary endpoint in the study. Lumateperone monotherapy was associated with significant improvement of major depressive episodes in ...

Researchers have identified seven clinical features that could help distinguish patients with bipolar disorder from those with major depressive disorder (MDD). “[O]ur result may have sufficient ...

Atypical features are prevalent in all subtypes of bipolar disorder, a Chinese survey published in Neuroscience Bulletin, shows, and are associated with the use of antidepressant medication in ...

LOS ANGELES — Mood episodes in patients with bipolar disorder (BD) that occur more frequently or severely during specific seasons — known as seasonality patterns — are associated with treatment ...

An antipsychotic approved by the FDA in 2009 to treat schizophrenia has now been green-lighted for use in bipolar 1 disorder. Iloperidone (Fanapt) is now FDA-approved for adults with bipolar 1 ...

Bipolar disorder exists on a spectrum rather than as a single, uniform condition. This fundamental characteristic explains why two people with the same diagnosis can experience dramatically different ...

Bipolar disorder is a long-term mood disorder characterized by major fluctuations in mood — both high and low — that can impact daily functioning and behavior. Although bipolar disorder is a chronic ...

Lumateperone 42mg was statistically significant on the primary endpoint of symptom reduction on the Montgomery Asberg Depression Rating Scale (MADRS) for each patient population including: -combined ...